Tocagen

Accelerate Brain Cancer Cure was the first non-profit to fund Tocagen's virally-based drug delivery and treatment system for brain cancer. Our investment enabled Tocagen to move forward and raise an additional $85 million in private funding. The project is now in the clinical trial phase.

Tocagen Inc. is a privately funded, clinical stage biopharmaceutical company pursuing the discovery, development and commercialization of gene therapy products for the treatment of cancer.

Tocagen's gene transfer technology uses a virus that will selectively spread in cancer tissue, while not harming normal tissue. Tocagen believes this therapeutic gene will behave like a Trojan horse killing the tumor cells from within without exposing the patient to high levels of chemotherapy that often cause toxicity.

Share |

Join us in our fight for a cure!

Twitter